High-risk genomic consensus validation for patients with newly diagnosed multiple myeloma using next-generation sequencingAnaïs Schavgoulidze, Jill Corre, Marie-Lorraine Chretien et al.|Blood|2025Cited by 15
First results of the rwe prospective study TEC care (IFM 2023-01) evaluating teclistamab in triple-class exposed relapsed refractory multiple myeloma patients.Aurore Perrot, Cyrille Touzeau, Cyrille Hulin et al.|Blood|2025Cited by 0